Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Tumor's genes reveal who can skip chemo?

NCT ID NCT03573791

Knowledge-focused Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This study aims to find biomarkers in tumor tissue that can predict whether a patient with locally advanced rectal cancer will resist neoadjuvant chemoradiotherapy. About half of patients do not respond well to this treatment, and identifying these patients beforehand could help them avoid unnecessary therapy and go straight to surgery. Researchers will compare gene expression profiles between patients who respond completely and those who do not, using RNA sequencing. The study involves 152 participants with stage II-III rectal cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which rectal cancer patients will not benefit from chemoradiotherapy, allowing them to proceed directly to surgery and avoid unnecessary side effects.
What could go wrong
This is an early-stage biomarker discovery study, and the findings may not translate into a reliable clinical test. The results will need validation in larger, independent groups of patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 152 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2018

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All participants will be recruited from Wuhan Union Hospital or Hubei Cancer Hospital.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathology proved to be adenocarcinoma of the rectum. * The edge of tumor is within 12cm of anus margin. * According to the eighth edition of AJCC TNM staging standard ,that staging for Ⅱ-Ⅲ period, as T3-T4, N0 or any T, N1-2. * There is no history of chemotherapy, radiotherapy or immunotherapy before neoadjuvant therapy. * Understand and agree to sign the informed consent for the study. Exclusion Criteria: * With intestinal obstruction or impending obstruction, or perforation. * With other malignancies occurred within 5 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer of rectum are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rectal cancer rectal carcinoma rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer of rectum Cancer of the rectum Neoplasms, rectal Rectal cancer Rectal tumors Rectum cancer Rectum neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hubei Cancer Hospital

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430079, China

  • Wuhan Union Hospital

    RECRUITING

    Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.